Results 111 to 120 of about 27,659 (185)

New P2Y12 blockers

, 2009
A number of new antiplatelet agents currently in development are anticipated to improve clinical outcomes and safety benefits in patientswith acute coronary syndrome (ACS).
M. Cattaneo
core   +1 more source

Does the VerifyNow P2Y12 assay overestimate “therapeutic response” to clopidogrel?

In contrast to short thrombelastography (s-TEG) which utilises adenosine diphosphate (ADP) alone, the VerifyNow P2Y12 assay (VN-P2Y12) additionally uses prostaglandin E1 (PGE1) as agonist to assess response to P2Y12 inhibitors.
Englyst, N., Khanna, V., Hobson, A., Mikael, R., Curzen, N., Sambu, N.   +5 more
core   +1 more source

P2Y12 Platelet Function Assay for Assessment of Bleeding Risk in Coronary Artery Bypass Grafting

, 2014
Background The use of platelet function testing has been advocated to individualize the time needed between discontinuation of P2Y12 inhibitors and coronary artery bypass grafting (CABG).
Dellis, S. L., Hartman, A. R., Yu, P. J., Cassiere, H. A., Stein, J., Manetta, F.   +5 more
core   +1 more source

Die Rolle des P2Y12-Rezeptors in adipozytärem Gewebe [PDF]

In dieser Studie konnte gezeigt werden, dass der P2Y12-Rezeptor sowohl in ausdifferenzierten murinen als auch in humanen braunen und weißen Adipozyten exprimiert wird. Die Expression ließ sich sowohl durch Ernährung als auch durch die Umgebungstemperatur
Bienert, Simon
core   +1 more source

Oligodendrocytes express P2Y12 metabotropic receptor in adult rat brain

, 2006
In the CNS, nucleotide receptors termed P2 receptors are identified on neurons and glial cells, mediating neuron-neuron, glia-glia and glia-neuron communication.
Bernardi G, Tramini G, Amadio S, Viscomi MT, Sancesario G, Volonté C., Martorana A, MARTORANA, ALESSANDRO, SANCESARIO, GIUSEPPE   +8 more
core   +1 more source

Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors

, 2014
Polypharmacy in patients undergoing coronary artery stenting or in those presenting with an acute coronary syndrome is common. Nevertheless, the risk of drug-drug interactions in patients treated simultaneously with P2Y12 receptor inhibitors is less well
Siller-Matula, Jolanta M., Krähenbühl, S., Delle-Karth, Georg, Siller-Matula, J. M., Delle-Karth, G., Michelson, Alan D., Trenk, Dietmar, Michelson, A. D., Trenk, D.   +8 more
core   +1 more source

Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction — 2023 ESC recommendations and scientific evidence. Is clinical evidence sufficient to suggest a move towards precision medicine? The ELECTRA-SIRIO 2 investigators’ viewpoint

Cardiology Journal
The 2023 ESC guidelines changed previously recommended a strategy of early treatment in patients with STEMI. Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients undergoing a primary PCI strategy (Class IIb, Level of evidence B ...
Jacek Kubica, Piotr Adamski, Jolita Badariene, Marc Bonaca, Piotr Buszman, Rahima Gabulova, Robert Gajda, Tobias Geisler, Robert Gil, Diana A. Gorog, Paul A. Gurbel, Tomasz Hajdukiewicz, Bartosz Hudzik, Stefan James, Young-Hoon Jeong, Adam Kern, Wacław Kochman, Aldona Kubica, Wiktor Kuliczkowski, Przemysław Magielski, Piotr Niezgoda, Małgorzata Ostrowska, Paolo Raggi, Uzeyir Rahimov, Grzegorz Skonieczny, Jolanta M. Siller-Matula, Giuseppe Specchia, Łukasz Szarpak, Paweł Szymański, Udaya Tantry, Julia Umińska, Eliano Pio Navarese   +31 more
doaj   +1 more source

Abstracts from the 2026 Congress of the Scandinavian Society of Anesthesiology and Intensive Care Medicine, Reykjavik, Iceland, June 10–12, 2026

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 9, October 2026.
wiley   +1 more source

High-mobility group box 1 increases platelet surface P2Y12 and platelet activation in sickle cell disease

JCI Insight
Thrombosis and inflammation are intimately linked and synergistically contribute to the pathogenesis of numerous thromboinflammatory diseases, including sickle cell disease (SCD).
Deirdre Nolfi-Donegan, Gowtham K. Annarapu, Claudette St. Croix, Michael Calderon, Cheryl A. Hillery, Sruti Shiva   +5 more
doaj   +1 more source

Routine CYP2C19 Genotyping, Antiplatelet Prescription Changes, and Clinical Outcomes After PCI in Chinese Patients With Coronary Heart Disease: A Single-Center Retrospective Study. [PDF]

Cardiol Res Pract
Niu D, Zhang M, Guan H.
europepmc   +1 more source